Skip to main content

Advertisement

Table 4 Multivariate analyses of prognostic factors for disease-specific survival of patients with early or advanced stage tumors in the study cohort

From: Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma

Variables Categories Early stage Advanced stage
   HR 95 % CI P valueb HR 95 % CI P valueb
Age (years) ≥60/<60 1.705 0.860-3.381 0.127 2.229 1.264-3.932 0.006
Sex Male/female 0.818 0.462-1.447 0.489 1.575 0.934-2.658 0.089
Tumor location Colon/rectum 1.095 0.802-1.495 0.569 0.968 0.727-1.290 0.826
Tumor size (cm) ≥5/<5 0.920 0.536-1.579 0.762 1.558 0.915-2.652 0.103
No. of examined lymph nodes ≥12/< 12 1.525 0.785-2.964 0.213 0.584 0.351-0.973 0.039
Bowel obstruction/perforation Yes/no 1.365 0.175-10.672 0.767 0.689 0.209-2.269 0.541
Adjuvant chemotherapya Yes/no 0.808 0.397-1.644 0.556    
Differentiation grade Poor/well + moderate 0.690 0.207-2.298 0.545 1.591 0.946-2.678 0.080
NETO2 expression High/low 1.937 1.107-3.390 0.021 2.241 1.245-4.035 0.007
  1. Abbreviations: HR, hazard ratio; 95 % CI, 95 % confidence interval
  2. aAs all advanced stage patients had received adjuvant chemotherapy, adjuvant chemotherapy was not enrolled into the multivariate analysis
  3. bBold type indicates statistical significance